AIM: To investigate the adipokine levels of leptin, adiponectin, resistin, visfatin, retinol-binding protein 4 (RBP4), apelin in alcoholic liver cirrhosis (ALC). METHODS: Forty non-diabetic ALC patients [median age: 59 years, males: 35 (87.5%), Child-Pugh (CP) score: median 7 (5-12), CP A/B/C: 18/10/12, Model for End-stage Liver Disease (MELD): median 10 (6-25), follow-up: median 32.5 mo (10-43)] were prospectively included. The serum adipokine levels were estimated in duplicate by ELISA. Somatometric characteristics were assessed with tetrapolar bioelectrical impedance analysis. Pearson's rank correlation coefficient was used to assess possible associations with adipokine levels. Univariate and multivariate Cox regression analysis was used to determine independent predictors for overall survival. RESULTS: Body mass index: median 25.9 (range: 20.1-39.3), fat: 23.4% (7.6-42.1), fat mass: 17.8 (5.49-45.4), free fat mass: 56.1 (39.6-74.4), total body water (TBW): 40.6 (29.8-58.8). Leptin and visfatin levels were positively associated with fat mass (P < 0.001/P = 0.027, respectively) and RBP4 with TBW (P = 0.025). Median adiponectin levels were significantly higher in CPC compared to CPA (CPA: 7.99 ± 14.07, CPB: 7.66 ± 3.48, CPC: 25.73 ± 26.8, P = 0.04), whereas median RBP4 and apelin levels decreased across the spectrum of disease severity (P = 0.006/P = 0.034, respectively). Following adjustment for fat mass, visfatin and adiponectin levels were significantly increased from CPA to CPC (both P < 0.001), whereas an inverse correlation was observed for both RBP4 and apelin (both P < 0.001). In the multivariate Cox regression analysis, only MELD had an independent association with overall survival (HR = 1.53, 95%CI: 1.05-2.32; P = 0.029). CONCLUSION: Adipokines are associated with deteriorating liver function in a complex manner in patients with alcoholic liver cirrhosis.
AIM: To investigate the adipokine levels of leptin, adiponectin, resistin, visfatin, retinol-binding protein 4 (RBP4), apelin in alcoholic liver cirrhosis (ALC). METHODS: Forty non-diabetic ALCpatients [median age: 59 years, males: 35 (87.5%), Child-Pugh (CP) score: median 7 (5-12), CP A/B/C: 18/10/12, Model for End-stage Liver Disease (MELD): median 10 (6-25), follow-up: median 32.5 mo (10-43)] were prospectively included. The serum adipokine levels were estimated in duplicate by ELISA. Somatometric characteristics were assessed with tetrapolar bioelectrical impedance analysis. Pearson's rank correlation coefficient was used to assess possible associations with adipokine levels. Univariate and multivariate Cox regression analysis was used to determine independent predictors for overall survival. RESULTS: Body mass index: median 25.9 (range: 20.1-39.3), fat: 23.4% (7.6-42.1), fat mass: 17.8 (5.49-45.4), free fat mass: 56.1 (39.6-74.4), total body water (TBW): 40.6 (29.8-58.8). Leptin and visfatin levels were positively associated with fat mass (P < 0.001/P = 0.027, respectively) and RBP4 with TBW (P = 0.025). Median adiponectin levels were significantly higher in CPC compared to CPA (CPA: 7.99 ± 14.07, CPB: 7.66 ± 3.48, CPC: 25.73 ± 26.8, P = 0.04), whereas median RBP4 and apelin levels decreased across the spectrum of disease severity (P = 0.006/P = 0.034, respectively). Following adjustment for fat mass, visfatin and adiponectin levels were significantly increased from CPA to CPC (both P < 0.001), whereas an inverse correlation was observed for both RBP4 and apelin (both P < 0.001). In the multivariate Cox regression analysis, only MELD had an independent association with overall survival (HR = 1.53, 95%CI: 1.05-2.32; P = 0.029). CONCLUSION: Adipokines are associated with deteriorating liver function in a complex manner in patients with alcoholic liver cirrhosis.
Authors: R Testa; R Franceschini; E Giannini; A Cataldi; F Botta; A Fasoli; P Tenerelli; E Rolandi; T Barreca Journal: J Hepatol Date: 2000-07 Impact factor: 25.083
Authors: Frank Tacke; Torsten Wüstefeld; Rüdiger Horn; Tom Luedde; Annavarapu Srinivas Rao; Michael P Manns; Christian Trautwein; Georg Brabant Journal: J Hepatol Date: 2005-05 Impact factor: 25.083
Authors: Paul Angulo; Laura M Alba; Lydia M Petrovic; Leon A Adams; Keith D Lindor; Michael D Jensen Journal: J Hepatol Date: 2004-12 Impact factor: 25.083
Authors: Evan D Muse; Silvana Obici; Sanjay Bhanot; Brett P Monia; Robert A McKay; Michael W Rajala; Philipp E Scherer; Luciano Rossetti Journal: J Clin Invest Date: 2004-07 Impact factor: 14.808
Authors: Uwe J F Tietge; Klaus H W Böker; Michael P Manns; Matthias J Bahr Journal: Am J Physiol Endocrinol Metab Date: 2004-03-09 Impact factor: 4.310
Authors: Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis Journal: Int J Mol Sci Date: 2017-06-29 Impact factor: 5.923
Authors: Michał Kukla; Marek Waluga; Michał Żorniak; Agnieszka Berdowska; Piotr Wosiewicz; Tomasz Sawczyn; Rafał J Bułdak; Marek Ochman; Katarzyna Ziora; Tadeusz Krzemiński; Marek Hartleb Journal: World J Gastroenterol Date: 2017-04-14 Impact factor: 5.742